CD4-Specific Designed Ankyrin Repeat Proteins Are Novel Potent HIV Entry Inhibitors with Unique Characteristics

Here, we describe the generation of a novel type of HIV entry inhibitor using the recently developed Designed Ankyrin Repeat Protein (DARPin) technology. DARPin proteins specific for human CD4 were selected from a DARPin DNA library using ribosome display. Selected pool members interacted specifically with CD4 and competed with gp120 for binding to CD4. DARPin proteins derived in the initial selection series inhibited HIV in a dose-dependent manner, but showed a relatively high variability in their capacity to block replication of patient isolates on primary CD4 T cells. In consequence, a second series of CD4-specific DARPins with improved affinity for CD4 was generated. These 2nd series DARPins potently inhibit infection of genetically divergent (subtype B and C) HIV isolates in the low nanomolar range, independent of coreceptor usage. Importantly, the actions of the CD4 binding DARPins were highly specific: no effect on cell viability or activation, CD4 memory cell function, or interference with CD4-independent virus entry was observed. These novel CD4 targeting molecules described here combine the unique characteristics of DARPins—high physical stability, specificity and low production costs—with the capacity to potently block HIV entry, rendering them promising candidates for microbicide development.

[1]  A. Smolyar,et al.  Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Plückthun,et al.  Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.

[3]  A. Trkola,et al.  Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors , 2005, Journal of Virology.

[4]  M. Berenbaum,et al.  A method for testing for synergy with any number of agents. , 1978, The Journal of infectious diseases.

[5]  D. Röthlisberger,et al.  In vitro selection and characterization of DARPins and Fab fragments for the co-crystallization of membrane proteins: The Na(+)-citrate symporter CitS as an example. , 2007, Journal of structural biology.

[6]  E. Padlan,et al.  A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. , 1997, AIDS research and human retroviruses.

[7]  B. Friedland,et al.  Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa , 2007, Journal of acquired immune deficiency syndromes.

[8]  A. Trkola,et al.  Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. , 2004, Blood.

[9]  Z. Grossman,et al.  HIV preferentially infects HIV-specific CD4+ T cells , 2002, Nature.

[10]  E. Check Scientists rethink approach to HIV gels , 2007, Nature.

[11]  John P. Moore,et al.  HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. , 2007, Virology.

[12]  S. Loewe,et al.  Die quantitativen Probleme der Pharmakologie , 1928 .

[13]  A. Plückthun,et al.  Isolation of Intracellular Proteinase Inhibitors Derived from Designed Ankyrin Repeat Proteins by Genetic Screening* , 2006, Journal of Biological Chemistry.

[14]  Christine Katlama,et al.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.

[15]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[16]  I. M. Belyakov,et al.  Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. , 2004, Immunity.

[17]  Q. Sattentau,et al.  A region in domain 1 of CD4 distinct from the primary gp120 binding site is involved in HIV infection and virus-mediated fusion. , 1991, The Journal of biological chemistry.

[18]  E. Reinherz,et al.  Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding , 1988, Nature.

[19]  G. Ramjee,et al.  South Africa's Experience of the Closure of the Cellulose Sulphate Microbicide Trial , 2007, PLoS medicine.

[20]  Q. Sattentau,et al.  A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells , 1992, Journal of virology.

[21]  Feng Gao,et al.  Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa , 2006, Journal of Virology.

[22]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[23]  E. Coligan Current protocols in immunology , 1991 .

[24]  J. J. Rosa,et al.  Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. , 1992, Journal of immunology.

[25]  L. Margolis,et al.  The Nonnucleoside Reverse Transcriptase Inhibitor UC-781 Inhibits Human Immunodeficiency Virus Type 1 Infection of Human Cervical Tissue and Dissemination by Migratory Cells , 2005, Journal of Virology.

[26]  A. Gettie,et al.  A Fusion Inhibitor Prevents Spread of Immunodeficiency Viruses, but Not Activation of Virus-Specific T Cells, by Dendritic Cells , 2008, Journal of Virology.

[27]  A. Hamad,et al.  Potent T Cell Activation with Dimeric Peptide–Major Histocompatibility Complex Class II Ligand: The Role of CD4 Coreceptor , 1998, The Journal of experimental medicine.

[28]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.

[29]  Andreas Plückthun,et al.  Selection and Characterization of Her2 Binding-designed Ankyrin Repeat Proteins* , 2006, Journal of Biological Chemistry.

[30]  A. B. Lyons,et al.  Determination of lymphocyte division by flow cytometry. , 1994, Journal of immunological methods.

[31]  Eric Hunter,et al.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.

[32]  A. Plückthun,et al.  Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. , 2006, Protein engineering, design & selection : PEDS.

[33]  J. Balzarini,et al.  Microbicide drug candidates to prevent HIV infection , 2007, The Lancet.

[34]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[35]  Andreas Plückthun,et al.  Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target , 2007, Nature Methods.

[36]  H. Lahm,et al.  Characterization of recombinant human interleukin-2 with micromethods. , 1985, Journal of chromatography.

[37]  Beda Joos,et al.  Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. , 2004, Virology.

[38]  William C. Olson,et al.  Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5 , 1999, Journal of Virology.

[39]  A. Stone Microbicides: a new approach to preventing HIV and other sexually transmitted infections , 2002, Nature Reviews Drug Discovery.

[40]  John P. Moore,et al.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120 , 2003, Nature Medicine.

[41]  Andreas Plückthun,et al.  Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. , 2003, Journal of molecular biology.

[42]  Q. Sattentau,et al.  A highly selected panel of anti‐CD4 antibodies fails to induce anti‐idiotypic antisera mediating human immunodeficiency virus neutralization , 1991, European journal of immunology.

[43]  M. Stumpp,et al.  DARPins: a true alternative to antibodies. , 2007, Current opinion in drug discovery & development.

[44]  M. Lederman,et al.  Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5 , 2004, Science.

[45]  D. Montefiori,et al.  Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.

[46]  Andreas Plückthun,et al.  Intracellular Kinase Inhibitors Selected from Combinatorial Libraries of Designed Ankyrin Repeat Proteins* , 2005, Journal of Biological Chemistry.

[47]  A. Plückthun,et al.  Directed in Vitro Evolution and Crystallographic Analysis of a Peptide-binding Single Chain Antibody Fragment (scFv) with Low Picomolar Affinity* , 2004, Journal of Biological Chemistry.

[48]  A. Plückthun,et al.  In vitro selection and evolution of functional proteins by using ribosome display. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Choyke,et al.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan , 2007, Nature Medicine.

[50]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[51]  R. Aitken,et al.  The search for a topical dual action spermicide/microbicide. , 2007, Current medicinal chemistry.

[52]  Ellis L. Reinherz,et al.  T Cell Receptor Binding to a pMHCII Ligand Is Kinetically Distinct from and Independent of CD4* , 2001, The Journal of Biological Chemistry.

[53]  Patrick M Liu,et al.  Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. , 2002, Toxicology.

[54]  W. Koff,et al.  Scientific and policy challenges to development of an AIDS vaccine , 2007, The Lancet.

[55]  John P. Moore,et al.  Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. , 2008, Annual review of medicine.

[56]  Amalio Telenti,et al.  HIV entry inhibitors , 2007, The Lancet.

[57]  Andreas Plückthun,et al.  A designed ankyrin repeat protein evolved to picomolar affinity to Her2. , 2007, Journal of molecular biology.

[58]  A. Trkola,et al.  Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5 , 1996, AIDS.

[59]  A. Plückthun,et al.  Designed to be stable: Crystal structure of a consensus ankyrin repeat protein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. Koup,et al.  Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. , 1995, AIDS research and human retroviruses.

[61]  A. Trkola,et al.  In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10 , 2007, Journal of Virology.

[62]  Q. Sattentau,et al.  Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding , 1990, The Journal of experimental medicine.

[63]  A. Trkola,et al.  The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. , 2000, The Journal of infectious diseases.

[64]  Xu Liu,et al.  Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster Virus , 2001, Clinical Diagnostic Laboratory Immunology.

[65]  E. Rieber,et al.  Antibody and HIV-1 gpl20 recognition of CD4 undermines the concept of mimicry between antibodies and receptors , 1992, Nature.

[66]  D. Kuritzkes,et al.  Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. , 2004, The Journal of infectious diseases.

[67]  A. Plückthun,et al.  High-affinity binders selected from designed ankyrin repeat protein libraries , 2004, Nature Biotechnology.

[68]  H. Katinger,et al.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.

[69]  Robin Shattock,et al.  In Vitro and In Vivo: The Story of Nonoxynol 9 , 2005, Journal of acquired immune deficiency syndromes.

[70]  P. Li,et al.  Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1 , 2002, Nature Immunology.

[71]  C. Briand,et al.  Drug Export Pathway of Multidrug Exporter AcrB Revealed by DARPin Inhibitors , 2006, PLoS biology.

[72]  J. Moore,et al.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.

[73]  F. Uckun,et al.  Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. , 2006, The Journal of antimicrobial chemotherapy.

[74]  Peter Reichelt,et al.  Single step protocol to purify recombinant proteins with low endotoxin contents. , 2006, Protein expression and purification.

[75]  G. Doncel Exploiting common targets in human fertilization and HIV infection: development of novel contraceptive microbicides. , 2006, Human reproduction update.

[76]  J. Fujisawa,et al.  Real-time analysis of human immunodeficiency virus type 1 Env-mediated membrane fusion by fluorescence resonance energy transfer. , 2006, Microbes and infection.

[77]  John P. Moore,et al.  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion , 2005, Nature.

[78]  Andreas Plückthun,et al.  Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. , 2007, Structure.